Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Celgene Corp., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Short-term borrowings and current portion of long-term debt	501)	—)	501)	—)	606)
Accounts payable	418)	305)	247)	241)	198)
Rebates, distributor chargebacks and distributor services	1,107)	814)	561)	367)	233)
Compensation	391)	358)	414)	353)	318)
Clinical trial costs and grants	475)	622)	342)	255)	190)
Litigation-related loss contingency	—)	—)	199)	—)	—)
Interest	238)	173)	168)	170)	59)
Sales, use, value added, and other taxes	66)	59)	101)	69)	66)
Milestones payable	—)	62)	—)	—)	—)
Success payment liability	70)	—)	—)	—)	—)
Short-term contingent consideration and success payments	60)	—)	47)	109)	35)
Royalties, license fees and collaboration agreements	114)	52)	—)	—)	—)
Deferred tax liability	—)	—)	—)	—)	131)
Other	466)	383)	285)	324)	236)
Accrued expenses and other current liabilities	2,987)	2,523)	2,115)	1,648)	1,267)
Income taxes payable	78)	84)	41)	20)	13)
Current portion of deferred revenue	73)	75)	55)	61)	29)
Current liabilities	4,057)	2,987)	2,959)	1,969)	2,112)
Deferred revenue, net of current portion	73)	34)	28)	30)	28)
Income taxes payable	2,190)	2,490)	420)	324)	273)
Deferred income tax liabilities	2,753)	1,327)	—)	378)	556)
Other non-current tax liabilities	—)	—)	2,519)	2,519)	—)
Contingent consideration	103)	80)	1,443)	1,412)	1,245)
Deferred compensation and long-term incentives	243)	240)	215)	171)	151)
Contingent value rights	19)	42)	45)	52)	136)
Derivative contracts	21)	134)	1)	—)	—)
Other	91)	48)	68)	30)	50)
Other non-current liabilities	477)	544)	1,771)	1,664)	1,581)
Long-term debt, net of discount, excluding current portion	19,769)	15,838)	13,789)	14,250)	6,266)
Non-current liabilities	25,262)	20,233)	18,527)	19,166)	8,703)
Total liabilities	29,319)	23,220)	21,486)	21,134)	10,815)
Preferred stock, $.01 par value per share; none outstanding	—)	—)	—)	—)	—)
Common stock, $.01 par value per share	10)	10)	10)	9)	9)
Common stock in treasury, at cost	(26,336)	(20,243)	(16,281)	(14,052)	(10,699)
Additional paid-in capital	14,978)	13,806)	12,378)	11,119)	9,827)
Retained earnings	17,559)	13,061)	10,074)	8,074)	6,472)
Accumulated other comprehensive income (loss)	(50)	287)	419)	768)	915)
Stockholders’ equity	6,161)	6,921)	6,599)	5,919)	6,525)
Total liabilities and stockholders’ equity	35,480)	30,141)	28,086)	27,053)	17,340)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Celgene Corp. current liabilities increased from 2016 to 2017 and from 2017 to 2018.
Non-current liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Celgene Corp. non-current liabilities increased from 2016 to 2017 and from 2017 to 2018.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Celgene Corp. total liabilities increased from 2016 to 2017 and from 2017 to 2018.
Stockholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Celgene Corp. stockholders’ equity increased from 2016 to 2017 but then decreased significantly from 2017 to 2018.

Celgene Corp. (NASDAQ:CELG)

Balance Sheet: Liabilities and Stockholders’ Equity